---
title: "Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Dosing and administration questions"
description: "Dosing and administration questions on Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing. Questions: What is the KEYTRUDA dose for high-risk early-stage TNBC? Can the KEYTRUDA dose be reduced for side effects? 2 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/dosing-and-administration"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Dosing and administration questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Keytruda](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf)

## Dosing

<a id="keytruda-early-tnbc-dosing"></a>

### What is the KEYTRUDA dose for high-risk early-stage TNBC?

> “Adult patients with high-risk early-stage
> TNBC
> 200 mg every 3 weeks
> or
> 400 mg every 6 weeks
> Administer KEYTRUDA prior to
> chemotherapy when given on
> the same day.
> Neoadjuvant treatment in combination with
> chemotherapy for 24 weeks (8 doses of
> 200 mg every 3 weeks or 4 doses of
> 400 mg every 6 weeks) or until disease
> progression or unacceptable toxicity,
> followed by adjuvant treatment with
> KEYTRUDA as a single agent for up to
> 27 weeks (9 doses of 200 mg every
> 3 weeks or 5 doses of 400 mg every
> 6 weeks) or until disease recurrence or
> unacceptable toxicity<sup>‡</sup>”

Source: [KEYTRUDA: Prescribing information, page 11, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf#page=11)

> “Patients who experience disease progression or unacceptable toxicity related to KEYTRUDA with neoadjuvant
> treatment in combination with chemotherapy should not receive adjuvant single agent KEYTRUDA.”

Source: [KEYTRUDA: Prescribing information, page 11, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf#page=11)

> “Administer diluted solution via infusion pump intravenously over 30 minutes through an intravenous line containing a sterile, nonpyrogenic, low-protein binding 0.2 to 5 micron in-line or add-on filter.”

Source: [KEYTRUDA: Preparation, Storage and Administration of KEYTRUDA® (pembrolizumab) | HCP, captured 2026-11-08](https://www.keytrudahcp.com/dosing/preparation-storage-administration/#:~:text=Administer%20diluted%20solution%20via%20infusion,micron%20in%2Dline%20or%20add%2Don%20filter.)

<a id="keytruda-dose-modifications"></a>

### Can the KEYTRUDA dose be reduced for side effects?

> “No dose reduction for KEYTRUDA is recommended.
> In general, withhold KEYTRUDA for severe (Grade 3) immune-mediated adverse reactions.
> Permanently discontinue KEYTRUDA for:
> Life-threatening (Grade 4) immune-mediated adverse reactions.
> Recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment.
> An inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks of initiating steroids.”

Source: [KEYTRUDA: Dose Modifications for Adverse Reactions for KEYTRUDA® (pembrolizumab) | HCP, captured 2026-11-08](https://www.keytrudahcp.com/dosing/dose-modifications/#:~:text=No%20dose%20reduction%20for%20KEYTRUDA,12%20weeks%20of%20initiating%20steroids.)

## Related pages
- [Medical information: Keytruda (pembrolizumab): High-risk early-stage triple-negative breast cancer](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/specific-populations)
- [Storage and supply](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/guidelines)
